TABLE 4.
Univariate analyses of irAEs’ earliest occurrence time with Cox regression models.
| Covariate | Univariate analysis (n = 44) | |||
|---|---|---|---|---|
| HR | 95.0% CI | p-value | ||
| Group 1 | ||||
| PD-1 | Reference | |||
| PD-1/TACE | 0.099 | 0.019 | 0.513 | 0.006 |
| PD-1/TKI | 0.513 | 0.148 | 1.778 | 0.293 |
| PD-1/TKI/TACE | 0.169 | 0.051 | 0.565 | 0.004 |
| Group 2 | ||||
| TKI | Reference | |||
| Non-TKI | 2.410 | 1.124 | 5.165 | 0.095 |
| Group 3 | ||||
| TACE | Reference | |||
| Non-TACE | 0.273 | 0.132 | 0.566 | <0.0001 |
Comparison of irAEs’ earliest occurrence time between patients receiving PD-1 inhibitors alone or in combination with TKI and TACE.